Diasome Pharmaceuticals, Inc. is focused on the clinical and commercial development of breakthrough therapies for diabetes and obesity. The Company conducts research and development in the fields of cell receptor targeting, insulin replacement, and hepatic (liver) glucose metabolism and its pipeline includes multiple injected and oral formulations of liver targeted insulins for both Type 1 and Type 2 diabetic patients that are Phase 3 ready. In addition, Diasome is developing a first-in-class oral compound for the Type 2 diabetes population that is based upon new insights into normal glucose metabolism and a novel mechanism of action, along with a nanotechnology-based oral compound that may have a significant impact in treating obesity.
|HQ||Cleveland, OH, US||Map|
|Employees (est.) (Apr 2021)||8|
Diasome total Funding
Diasome latest funding size
Time since last funding
|4 years ago|
|Medicxi Ventures, Black Beret Life Sciences, JDRF T1D Fund, McDonald Partners|
Diasome has 4.58k Twitter Followers. The number of followers has decreased 0.2% month over month and decreased 1.1% quarter over quarter
When was Diasome founded?
Diasome was founded in 2004.
Who are Diasome key executives?
Diasome's key executives are Robert Geho, W. Blair Geho and Douglas Muchmore.
How many employees does Diasome have?
Diasome has 8 employees.
Who are Diasome competitors?
Competitors of Diasome include Lobesity, InVivo Therapeutics and Enthera Pharmaceuticals.
Where is Diasome headquarters?
Diasome headquarters is located at 10000 Cedar Ave #6, Cleveland.
Where are Diasome offices?
Diasome has an office in Cleveland.
How many offices does Diasome have?
Diasome has 1 office.
Receive alerts for 300+ data fields across thousands of companies